

# Slc26a6 regulates CFTR activity *in vivo* to determine pancreatic duct HCO<sub>3</sub><sup>-</sup> secretion: relevance to cystic fibrosis

Youxue Wang<sup>1</sup>, Abigail A Soyombo<sup>1</sup>,  
Nikolay Shcheynikov<sup>1</sup>, Weizhong Zeng<sup>1</sup>,  
Michael Dorwart<sup>1</sup>, Christopher R Marino<sup>2</sup>,  
Philip J Thomas<sup>1</sup> and Shmuel Muallem<sup>1,\*</sup>

<sup>1</sup>The Department of Physiology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA and <sup>2</sup>Department of Medicine, University of Tennessee, Memphis, TN, USA

Fluid and HCO<sub>3</sub><sup>-</sup> secretion are vital functions of the pancreatic duct and other secretory epithelia. CFTR and Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity at the luminal membrane are required for these functions. The molecular identity of the Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers and their relationship with CFTR in determining fluid and HCO<sub>3</sub><sup>-</sup> secretion are not known. We show here that the Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchanger *slc26a6* controls CFTR activity and ductal fluid and HCO<sub>3</sub><sup>-</sup> secretion. Unexpectedly, deletion of *slc26a6* in mice and measurement of fluid and HCO<sub>3</sub><sup>-</sup> secretion into sealed intralobular pancreatic ducts revealed that deletion of *slc26a6* enhanced spontaneous and decreased stimulated secretion. Remarkably, inhibition of CFTR activity with CFTR<sub>inh</sub>-172, knock-down of CFTR by siRNA and measurement of CFTR current in WT and *slc26a6*<sup>-/-</sup> duct cells revealed that deletion of *slc26a6* resulted in dis-regulation of CFTR activity by removal of tonic inhibition of CFTR by *slc26a6*. These findings reveal the intricate regulation of CFTR activity by *slc26a6* in both the resting and stimulated states and the essential role of *slc26a6* in pancreatic HCO<sub>3</sub><sup>-</sup> secretion *in vivo*.

The EMBO Journal (2006) 25, 5049–5057. doi:10.1038/sj.emboj.7601387; Published online 19 October 2006

Subject Categories: membranes & transport; molecular biology of disease

Keywords: CFTR; fluid and HCO<sub>3</sub><sup>-</sup> secretion; pancreatic duct; *slc26a6*

## Introduction

Most epithelia secrete fluid containing a high concentration of HCO<sub>3</sub><sup>-</sup>; chief among them is the pancreatic duct, which secretes a fluid containing up to 140 mM HCO<sub>3</sub><sup>-</sup> while absorbing most of the Cl<sup>-</sup> from the pancreatic juice (Steward *et al*, 2005). In addition to serving as the biological buffer, HCO<sub>3</sub><sup>-</sup> is a chaotropic anion that facilitates solubilization of macro-

molecules, such as digestive enzymes and mucins, in biological fluids. HCO<sub>3</sub><sup>-</sup> also reduces the binding of pathogenic bacteria to mucins (Choi *et al*, 2001). The essential role of epithelial Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion is best exemplified in cystic fibrosis (CF), in which aberrant Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion (Wilschanski and Durie, 1998; Sokol, 2001) leads to destruction of the airway epithelia, the pancreas and the vas deferens (Wilschanski and Durie, 1998). Aberrant CFTR-dependent HCO<sub>3</sub><sup>-</sup> secretion is likely to contribute to the development of chronic pancreatitis (Lee *et al*, 2003; Cohn, 2005).

The mechanism of epithelial Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion, including by the pancreas is poorly understood (Cook *et al*, 1994; Kunzelmann and Mall, 2002; Melvin *et al*, 2005; Steward *et al*, 2005). A breakthrough was made with the discovery of the new family of luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers, the SLC26 transporters (Mount and Romero, 2004). Members of the family play an important role in many epithelial functions. Several diseases have been linked to mutations in members of the family, including Dystrophic Dysplasia (SLC26A2) (Superti-Furga *et al*, 1996), Congenital Chloride Diarrhea (SLC26A3) (Makela *et al*, 2002), Pendred's syndrome (SLC26A4) (Everett *et al*, 1997) and hearing loss (SLC26A5) (Liu *et al*, 2003). The absence of *slc26a6* can lead to calcium-oxalate urolithiasis (Jiang *et al*, 2006).

Several members of the family show restricted expression, while others, including SLC26A6, are ubiquitous (Mount and Romero, 2004). Their role in epithelial HCO<sub>3</sub><sup>-</sup> secretion was proposed by their ability to mediate Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. In a recent work, we showed that *slc26a3* and *slc26a6* are electrogenic Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers and that *slc26a6* functions as a 1Cl<sup>-</sup>/2HCO<sub>3</sub><sup>-</sup> exchanger (Ko *et al*, 2002; Shcheynikov *et al*, 2006). Another notable finding is the prominent mutual activation of the SLC26 transporters and CFTR, which is mediated by the CFTR R domain and the SLC26 transporters STAS domain (Ko *et al*, 2004), suggesting that the SLC26 transporters participate in and regulate epithelia Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion. This possibility is further suggested by the reduced PGE<sub>2</sub>-stimulated intestinal HCO<sub>3</sub><sup>-</sup> secretion in the *slc26a6*<sup>-/-</sup> mouse (Tuo *et al*, 2006). However, a caveat in this work is that deletion of *slc26a6* had no effect on forskolin-stimulated HCO<sub>3</sub><sup>-</sup> secretion (Tuo *et al*, 2006), although both forskolin and PGE<sub>2</sub> act by increasing cellular cAMP. In the kidney and intestine, deletion of *slc26a6* reduced oxalate absorption (Wang *et al*, 2005; Freel *et al*, 2006; Jiang *et al*, 2006). However, how *slc26a6* affects and regulates HCO<sub>3</sub><sup>-</sup> secretion and what its role is in pancreatic HCO<sub>3</sub><sup>-</sup> secretion is not known. Also unknown is the role of *slc26a6* in fluid secretion.

Epithelial Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion is intimately regulated by CFTR (Cook *et al*, 1994; Wilschanski and Durie, 1998; Kunzelmann and Mall, 2002; Irokawa *et al*, 2004; Melvin *et al*, 2005; Steward *et al*, 2005). To understand the

\*Corresponding author. The Department of Physiology, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9040, USA. Tel.: +1 214 645 6008; Fax: +1 214 645 6089; E-mail: Shmuel.Muallem@UTSouthwestern.edu

Received: 15 May 2006; accepted: 18 September 2006; published online: 19 October 2006

role of slc26a6 in pancreatic Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion, we deleted slc26a6 from mice and measured fluid and HCO<sub>3</sub><sup>-</sup> secretion into sealed intralobular pancreatic ducts in primary culture. Unexpectedly, deletion of slc26a6 resulted in both enhanced spontaneous and suppressed stimulated fluid and HCO<sub>3</sub><sup>-</sup> secretion. Remarkably, this was due to removal of tonic inhibition of CFTR by slc26a6 in the resting duct and by reduced activation of CFTR by slc26a6 in stimulated ducts. These findings reveal for the first time the intricate regulation of CFTR activity by slc26a6 and the essential role of slc26a6 in pancreatic HCO<sub>3</sub><sup>-</sup> secretion *in vivo*.

## Results


### Slc26a6 and CFTR are essential for ductal fluid secretion

The pancreatic and salivary ducts secrete a fluid containing only 20 mM Cl<sup>-</sup> and as much as 140 mM HCO<sub>3</sub><sup>-</sup> (Cook *et al*, 1994; Melvin *et al*, 2005; Steward *et al*, 2005). How the ducts can generate such a fluid is not known. It is clear that CFTR plays an important role in this secretory process, as the absence of CFTR, either in CF (Wilschanski and Durie, 1998) or in CF mouse models (Clarke and Harline, 1998; Lee *et al*, 1999), markedly reduces Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion. However, CFTR is unlikely to directly mediate HCO<sub>3</sub><sup>-</sup> secretion by the WT ducts as the HCO<sub>3</sub><sup>-</sup> permeability of CFTR is low in the presence of normal luminal Cl<sup>-</sup> (Shcheynikov *et al*, 2004; Wright *et al*, 2004), and under physiological conditions, CFTR alone cannot produce a fluid containing 140 mM HCO<sub>3</sub><sup>-</sup> (Sohma *et al*, 2000; Steward *et al*, 2005). On the other hand, CFTR activates (Ko *et al*, 2002) and is activated by members of the SLC26A Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> transporters, including slc26a6 (Ko *et al*, 2004), which is expressed at high levels in the pancreatic duct (Lohi *et al*, 2000). Slc26a6 is an electrogenic Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchanger that mediates a 1Cl<sup>-</sup>/2HCO<sub>3</sub><sup>-</sup> exchange (Xie *et al*, 2002; Shcheynikov *et al*, 2006), and is likely to be essential for generation of the low Cl<sup>-</sup> high HCO<sub>3</sub><sup>-</sup> content of the pancreatic juice (Ko *et al*, 2004; Steward *et al*, 2005). Therefore, to


reveal the role of slc26a6 in pancreatic duct fluid and HCO<sub>3</sub><sup>-</sup> secretion, we generated slc26a6<sup>-/-</sup> mice by deletion of exons 6–9 that code for the predicted membrane spanning domains of slc26a6. Figure 1A shows the strategy used to produce the ES cells that were used to generate the slc26a6<sup>-/-</sup> mice and genotyping of WT, heterozygous and slc26a6<sup>-/-</sup> mice.

To assay the role of CFTR in fluid and HCO<sub>3</sub><sup>-</sup> secretion in sealed pancreatic ducts in primary culture, we downregulated CFTR with dicer siRNA. The dicer siRNA approach was used to study the effect of acute removal of CFTR and avoid the potential complications that may be encountered and the long time needed to generate mice that are deficient in both the CFTR and slc26a6 genes. The effectiveness of siRNA was evaluated by RT-PCR because the small amount of material from the cultured duct is not sufficient for Western blot analysis, and for an unknown reason the sealed ducts showed very poor staining in several immunofluorescence procedures tested. Figure 1B shows that siRNA2 most effectively downregulated CFTR mRNA in ducts from WT and slc26a6<sup>-/-</sup> mice. Real-time quantitative PCR (Q-PCR) in three separate duct preparation showed that dicer siRNA2 reduced CFTR mRNA by 65 ± 13% (Figure 1C). This dicer siRNA was used in all subsequent experiments.

Fluid secretion into the lumen of the sealed ducts results in expansion of the lumen, and measurement of the lumen volume before and after stimulation can be used to assay fluid secretion (Szalmay *et al*, 2001). This procedure was validated by injection of a known amount of fluorescently labeled fluid into non-secreting ducts and obtaining excellent correlation between the expected and measured change in lumen volume (Ishiguro *et al*, 1998). Figure 1D shows selective images of WT and slc26a6<sup>-/-</sup> sealed ducts incubated in HEPES-buffered media. After a control period of 10 min, the ducts were incubated in HCO<sub>3</sub><sup>-</sup>-buffered media. The gain in lumen volume in response to exposure to HCO<sub>3</sub><sup>-</sup> is considered as spontaneous secretion. Finally, the ducts were stimulated with the pancreatic secretagogue secretin. The time course of fluid secretion was measured by recording



**Figure 1** Deletion of slc26a6 in mice, knock down of CFTR and images of sealed duct. (A) Shows the vector used to delete the slc26a6 gene in mice, Southern blot of ES cells used to generate the mice and PCR with DNA prepared from WT and slc26a6<sup>-/-</sup> mice with the primers marked p1, p2 and p3. The two bands in the Southern blot of the ES cells are the WT (7.7 kb) and mutant (4.3 kb) alleles. In (B), mRNA was extracted from sealed WT and slc26a6<sup>-/-</sup> ducts that were treated with scrambled (control) and three CFTR-specific dicer siRNA and was used to evaluate the level of CFTR and actin mRNA by RT-PCR. Actin mRNA was used to verify that the same amount of mRNA was used in each sample. (C) Shows the results of Q-PCR of WT ducts treated with scrambled or CFTR-specific dicer siRNA2. The results show the mean ± s.e. from three duct preparations. (D) Shows the images of sealed WT and slc26a6<sup>-/-</sup> ducts incubated in HEPES and then HCO<sub>3</sub><sup>-</sup>-buffered media and stimulated with 30 nM secretin.



**Figure 2** Fluid secretion by sealed intralobular pancreatic duct. In (A, C), WT (circles) and *slc26a6*<sup>-/-</sup> ducts (squares) were treated with scrambled (filled symbols) and siRNA2 (open symbols) and cultured for 36–48 h. The ducts were incubated in HEPES-buffered media for 10 min and then in HCO<sub>3</sub><sup>-</sup>-buffered media for an additional 10 min before stimulation with 30 nM secretin (A) or 10 μM forskolin (C). Images were captured at a resolution of 2 (A) or 5 min/image (C). The means ± s.e. of 9–12 ducts in (A) and 4–6 ducts in (C) from four (A) and three (C) mice of each line are shown. The average diameter and length of the ducts in (A) were used to calculate the secretory rates in terms of pl/min/mm<sup>2</sup> (B). Secretory rates were calculated for the 10 min intervals in which the ducts were incubated in HEPES-, then HCO<sub>3</sub><sup>-</sup>-buffered media and the first 10 min of stimulation with secretin for WT (green columns) and *slc26a6*<sup>-/-</sup> ducts (blue columns). (For colour figure see online version.)

the images at 2 or 5 min intervals and the results are expressed as the ratio of volume at time *t*/volume at *t*=0 (*V<sub>t</sub>*/*V<sub>0</sub>*). This is possible as secretion before cell stimulation was similar in WT and *slc26a6*<sup>-/-</sup> ducts, as indicated by their similar diameter when incubated in HEPES-buffered media. Thus, the diameter of WT ducts treated with control and dicer siRNA averaged (*n* ≥ 18) 81 ± 7 and 78 ± 8 μm, respectively, and the diameter of *slc26a6*<sup>-/-</sup> ducts treated with control and dicer siRNA averaged (*n* ≥ 15) 82 ± 5 and 79 ± 5 μm, respectively.


Figure 2 shows the spontaneous and stimulated fluid secretion in WT and *slc26a6*<sup>-/-</sup> ducts and the obligatory role of CFTR in both activities. Incubation of WT ducts in HCO<sub>3</sub><sup>-</sup>-buffered media resulted in a small spontaneous fluid secretion (Figure 2B and C, gray circles). Stimulation of the duct with the physiological concentration of 30 nM secretin (Figure 2A, close circles and B) or with the supramaximal concentration of 10 μM forskolin (Figure 2C, close circles) markedly stimulated fluid secretion by the WT ducts. Notably, fluid secretion was nearly abolished by downregulation of CFTR with siRNA (Figure 2A, open circles and Figure 2B). A strikingly different pattern was observed with the *slc26a6*<sup>-/-</sup> ducts. First, deletion of *slc26a6* increased spontaneous fluid secretion (Figure 2A and C, close squares) that was most apparent on exposing the ducts to HCO<sub>3</sub><sup>-</sup>-buffered media. Second, deletion of *slc26a6* reduced secretin-stimulated fluid secretion by 77 ± 11% (Figure 2A and B, *n* = 8) and forskolin-stimulated fluid secretion by 63 ± 9% (Figure 2B, *n* = 6). Notably, the spontaneous and residual stimulated fluid secretions were inhibited by knock-down of CFTR (Figure 2A and C, gray open squares).

The results in Figure 2 have several important implications. CFTR is essential for all forms of ductal fluid secretion. Similarly, *slc26a6* modulates both forms of ductal fluid secretion. It suppresses the activity of the transporter mediating spontaneous secretion and it is required for stimulated ductal fluid secretion as stimulation of CFTR with secretin or forskolin in *slc26a6*<sup>-/-</sup> ducts did not elicit maximal fluid secretion. As CFTR is involved in both activities (Figure 2)

and *slc26a6* interacts with and regulates CFTR channel activity (Ko *et al*, 2004), it is likely that *slc26a6* regulates the activity of CFTR at the resting and stimulated state, resulting in the phenotype of the *slc26a6*<sup>-/-</sup> ducts. In addition, *slc26a6* may regulate the expression of CFTR and deletion of *slc26a6* may have resulted in upregulation of another pancreatic duct Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange. RT-PCR analysis revealed that the pancreatic duct expresses *slc26a2*, *slc26a3*, *slc26a6* and *slc26a11*. However, expression in oocytes showed that *slc26a2* and *slc26a11* are active as Cl<sup>-</sup> transporters but do not function as Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchangers (not shown). Therefore, we tested the effect of deletion of *slc26a6* on expression of CFTR and *slc26a3*. Figure 3A shows that expression level and localization of CFTR was the same in WT and *slc26a6*<sup>-/-</sup> ducts. As antibodies that reliably detect *slc26a3* in the pancreatic duct are not available, we evaluated the level of *slc26a3* mRNA by Q-PCR. Figure 3B shows that *slc26a3* mRNA was not upregulated in the pancreatic duct. To further verify this finding, we measured *slc26a3* mRNA in the submandibular (SMG) duct, another duct that secretes a high amount of HCO<sub>3</sub><sup>-</sup> and expresses the same SLC26 transporters as the pancreatic duct. Figure 3B shows that *slc26a3* mRNA was not altered in the SMG duct of *slc26a6*<sup>-/-</sup> mice.

#### ***Slc26a6* and CFTR determine resting and stimulated luminal HCO<sub>3</sub><sup>-</sup> permeability of the pancreatic duct**


Pancreatic ductal fluid secretion is coupled to Cl<sup>-</sup> absorption and HCO<sub>3</sub><sup>-</sup> secretion. Both CFTR (Poulsen *et al*, 1994; Linsdell *et al*, 1997) and *slc26a6* (Ko *et al*, 2002, 2004; Xie *et al*, 2002) were shown to function as HCO<sub>3</sub><sup>-</sup> transporters. Therefore, it was of interest to measure ductal HCO<sub>3</sub><sup>-</sup> transport and whether it is modified by *slc26a6*. In the first set of experiments, we measured Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in the sealed ducts by monitoring the change in intracellular pH (*pH<sub>i</sub>*) in response to removal and re-addition of bath Cl<sup>-</sup>. Two experimental protocols were used to evaluate the role of CFTR in this activity: inhibition of CFTR by the selective CFTR inhibitor CFTR<sub>inh</sub>-172 (Ma *et al*, 2002) and downregulation of CFTR with dicer siRNA. To economize on the use of



**Figure 3** Expression of CFTR and slc26a3 mRNA in WT and slc26a6<sup>-/-</sup> ducts. CFTR expression was evaluated by immunolocalization (A). Images captured randomly from slides prepared from the pancreas of two WT and two slc26a6<sup>-/-</sup> mice were used to determine the intensity of duct staining. Images were captured under identical image capture setting and thresholded before measurement of intensity of individual ducts (at least 10 in each image). The intensities were averaged and the ratio of staining intensity in slc26a6<sup>-/-</sup>/WT ducts is recorded in the first column in (B). mRNA was extracted from the pancreatic ducts of three WT and three slc26a6<sup>-/-</sup> mice and the SMG of two of these WT and slc26a6<sup>-/-</sup> mice. The mRNA was used to determine slc26a6 mRNA level by Q-PCR and the means ± s.e. or the slc26a6<sup>-/-</sup>/WT ratio is shown in (B).

inhibitor, the effect of CFTR<sub>inh</sub>-172 was tested by preincubating the ducts in HCO<sub>3</sub><sup>-</sup>-buffered medium, equilibrated with 5% CO<sub>2</sub> and containing 5 μM CFTR<sub>inh</sub>-172 for 15 min. The preincubation is required for the maximal inhibition of CFTR by CFTR<sub>inh</sub>-172. Perfusion commenced after this incubation with media that did not contain inhibitor and the effect of Cl<sup>-</sup> removal was tested within 1 min of the start of perfusion. This is possible as reversibility of inhibition of CFTR by CFTR<sub>inh</sub>-172 is slow, and after incubation with 1 μM CFTR<sub>inh</sub>-172, reversal of inhibition of CFTR required more than 10 min washout (see Ma *et al*, 2002). Figure 4A shows that CFTR<sub>inh</sub>-172 did not inhibit Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in WT ducts. In fact, CFTR<sub>inh</sub>-172 consistently slightly increased the rate of Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange, although in six ducts from two mice the increase did not reach statistical significance. Unexpectedly, deletion of slc26a6 markedly increased basal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity of the duct by about 72 ± 11%. In contrast with its effect in WT ducts, CFTR<sub>inh</sub>-172 inhibited the enhanced basal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in slc26a6<sup>-/-</sup> ducts by about 36 ± 6%.

The findings in Figure 4A provided the first evidence that CFTR activity was altered in the slc26a6<sup>-/-</sup> mice and that CFTR contributed to basal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in these ducts. To obtain independent evidence to support these findings, we tested the effect of downregulation of CFTR by siRNA on basal and stimulated Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity of WT and slc26a6<sup>-/-</sup> ducts. Figure 4B shows that stimulation of WT ducts with secretin enhanced Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity by 65 ± 9%. Knock-down of CFTR by siRNA had no effect on basal exchange activity but largely prevented secre-



**Figure 4** Properties of Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in WT and slc26a6<sup>-/-</sup> ducts. (A) Sealed ducts prepared from WT (black and red traces and columns) and slc26a6<sup>-/-</sup> ducts (blue and green traces and columns) were incubated for 15 min in HCO<sub>3</sub><sup>-</sup>-buffered media containing 5 μM CFTR<sub>inh</sub>-172 (red and green) or vehicles (black and blue-controls) before perfusion with Cl<sup>-</sup>-free and Cl<sup>-</sup>-containing medium for the indicated period of time. The mean ± s.e. of the rates of pH<sub>i</sub> change obtained with 5–7 ducts prepared from two WT and two slc26a6<sup>-/-</sup> mice are shown in the columns. #*P* < 0.01 relative to WT, \**P* < 0.05 relative to untreated slc26a6<sup>-/-</sup> ducts. WT (B) and slc26a6<sup>-/-</sup> ducts (C) were treated with scrambled (black and blue traces and columns) or sense siRNA2 (red and green traces and columns) and cultured for 36–48 h. The ducts were equilibrated in HCO<sub>3</sub><sup>-</sup>-buffered media and Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity was measured by alternately exposing the ducts to Cl<sup>-</sup>-free and Cl<sup>-</sup>-containing medium before and after stimulation with 30 nM secretin. The columns are the mean ± s.e. of at least six experiments from three WT and three slc26a6<sup>-/-</sup> mice. \**P* < 0.05 of the respective control, #*P* < 0.01 relative to unstimulated WT, †better than *P* < 0.001 relative to control slc26a6<sup>-/-</sup> ducts. (For colour figure see online version.)


tin-stimulated Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity. Stimulation of slc26a6<sup>-/-</sup> ducts with secretin slightly increased Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity over enhanced basal activity, but in eight experiments the stimulation did not reach statistical significance. Most notably, knock-down of CFTR almost completely inhibited Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity in slc26a6<sup>-/-</sup> ducts and stimulation of the ducts only slightly increased Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity (Figure 4C), probably due to incomplete knock-down of CFTR. Hence, siRNA was more effective in inhibiting Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity than CFTR<sub>inh</sub>-172, suggesting that Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity of the slc26a6<sup>-/-</sup> duct was mediated in part by CFTR and in part by a CFTR-dependent mechanism.

The protocol in Figure 4 assays the entire Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity of the ducts. To isolate the luminal

membrane HCO<sub>3</sub><sup>-</sup> permeability, we used the protocol developed by Szalmay *et al* (2001), in which the basolateral membrane HCO<sub>3</sub><sup>-</sup> influx mechanisms (Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransport by pNBC and Na<sup>+</sup>/H<sup>+</sup> exchange by NHE1) are inhibited with 4,4'-diisothiocyanatodihydrostilbene-2, 2'-disulfonic acid (H<sub>2</sub>DIDS) and HOE694 to uncover the HCO<sub>3</sub><sup>-</sup> permeability of the luminal membrane, which results in cytosolic acidification (see the model in Figure 5). Figure 5 shows that HCO<sub>3</sub><sup>-</sup> permeability of WT ducts was nearly doubled by stimulation with secretin. Knock-down of CFTR had no effect on basal HCO<sub>3</sub><sup>-</sup> permeability, but it reduced the HCO<sub>3</sub><sup>-</sup> permeability of secretin-stimulated ducts to that of unstimulated ducts (Figure 5, WT group). Deletion of *slc26a6* increased the basal luminal membrane HCO<sub>3</sub><sup>-</sup> permeability, which was minimally increased in response to stimulation with secretin. Knock-down of CFTR markedly inhibited the basal and stimulated

HCO<sub>3</sub><sup>-</sup> permeability of *slc26a6*<sup>-/-</sup> ducts to 39 ± 5 and 36 ± 5% of stimulated, siRNA-treated WT ducts, respectively (Figure 5, *slc26a6*<sup>-/-</sup> group).

The results in Figures 4 and 5 are consistent with those found by measurement of fluid secretion (Figure 2), further suggesting that fluid and HCO<sub>3</sub><sup>-</sup> secretion are coupled and mediated by the same transporters. Moreover, these findings indicate that *slc26a6* regulates the luminal membrane HCO<sub>3</sub><sup>-</sup> permeability that also requires the activity of CFTR. Although knock-down of CFTR markedly reduces luminal HCO<sub>3</sub><sup>-</sup> permeability in *slc26a6*<sup>-/-</sup> ducts, it is possible that CFTR regulates another luminal HCO<sub>3</sub><sup>-</sup> transporter, such as another SLC26 transporter, in *slc26a6*<sup>-/-</sup> ducts. This interpretation is supported by the finding that the siRNA was more effective than CFTR<sub>inh</sub>-172 in inhibiting Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange by the *slc26a6*<sup>-/-</sup> ducts. It is also clear that *slc26a6* inhibits the ability of CFTR to activate luminal HCO<sub>3</sub><sup>-</sup> permeability. We note that although the luminal HCO<sub>3</sub><sup>-</sup> permeability of *slc26a6*<sup>-/-</sup> ducts is as high as that of secretin-stimulated WT ducts, it does not support fluid secretion (compare Figure 2 and Figures 4 and 5). This indicates that the 1Cl<sup>-</sup>/2HCO<sub>3</sub><sup>-</sup> exchange activity of *slc26a6* (Ko *et al*, 2002, 2004; Xie *et al*, 2002) is required for stimulated ductal fluid secretion.



**Figure 5** Luminal HCO<sub>3</sub><sup>-</sup> permeability of WT and *slc26a6*<sup>-/-</sup> ducts. WT (blue, red, gold, torques traces and/or columns and definition next to traces and columns) and *slc26a6*<sup>-/-</sup> ducts (purple, violet, green, gray traces and/or columns) were treated with scrambled or sense siRNA2, incubated in HCO<sub>3</sub><sup>-</sup>-buffered media and, as indicated, stimulated with 30 nM secretin. The ducts were then treated with 1 μM HOE694 and 0.2 mM H<sub>2</sub>DIDS and the reduction in pH<sub>i</sub> was measured. The rate of changes in pH<sub>i</sub> (ΔpH/min) was calculated and expressed as % of that of WT. The results are the mean ± s.e. of at least six ducts from three WT and three *slc26a6*<sup>-/-</sup> mice. \**P* < 0.01 relative to unstimulated WT, #*P* < 0.01 relative to stimulated WT, \*\**P* < 0.01 relative to siRNA-treated WT. (For colour figure see online version.)


### Slc26a6 regulates resting and stimulated CFTR activity

The results in Figures 2–5 clearly suggest that *slc26a6* regulates the activity of CFTR in resting and stimulated ducts. In previous work, we showed that *slc26a3* and *slc26a6* activate stimulated CFTR (Ko *et al*, 2004). To examine the effect of *slc26a6* on the activity of CFTR, we coexpressed CFTR and *slc26a6* in *Xenopus* oocytes. Stimulation of cells expressing CFTR and CFTR + *slc26a6* with 1 or 10 μM forskolin showed that *slc26a6* increases the maximal current of CFTR. However, *slc26a6* reduces the rate of activation of CFTR and the reduction in rate was more pronounced when the intensity of CFTR stimulation (Figure 6A and B) was lower. The reduction in the rate of CFTR activation was specific for *slc26a6*, as *slc26a3*, which also potently activates CFTR (Ko *et al*, 2004), increased both the rate and the extent of CFTR activity (Figure 6A, *n* = 6).

To determine the effect of *slc26a6* on CFTR activity *in vivo*, we compared the rate of activation of CFTR by forskolin in WT and *slc26a6*<sup>-/-</sup> parotid duct cells that express high levels of CFTR (Ko *et al*, 2004). Figure 6C shows that deletion of *slc26a6* markedly increased the rate of activation of CFTR when the cells were stimulated with an intermediate concentration of 3 μM forskolin. Stimulation of duct cells with 10 μM forskolin resulted in similar rates of CFTR activation in WT and *slc26a6*<sup>-/-</sup> cells.

## Discussion

The findings in Figure 6C are the first to show regulation of native CFTR activity by any transporter and the combined results show that deletion of *slc26a6* resulted in dis-regulation of CFTR in the pancreatic duct. *Slc26a6* inhibits the activity of CFTR in the resting state, which likely prevents unnecessary fluid and HCO<sub>3</sub><sup>-</sup> secretion. This is evident from the increased HCO<sub>3</sub><sup>-</sup> permeability and fluid secretion in *slc26a6*<sup>-/-</sup> ducts that is eliminated by knock-down of CFTR. In addition, we showed previously that the pancreatic (Ahn *et al*, 2001) and salivary ducts (Luo *et al*, 2001; Park



**Figure 6** Regulation of CFTR by slc26a6. (A) Oocytes expressing CFTR (dark traces), CFTR and slc26a6 (green traces) or CFTR and slc26a3 (red trace) were stimulated with 1 or 10 μM forskolin, as indicated. The summary in (B) shows the mean ± s.e. of six experiments. (C) WT (blue traces and columns) and slc26a6<sup>-/-</sup> (green traces and columns) parotid duct cells were used to measure CFTR current stimulated with 3 (n = 7) or 10 μM (n = 9) forskolin. The columns show the mean ± s.e. of the time to peak current. (For colour figure see online version.)

*et al*, 2002) express the HCO<sub>3</sub><sup>-</sup> salvage mechanisms NHE3 and NBC3 that are active in the resting state and are inhibited by CFTR at the stimulated state (Ahn *et al*, 2001; Luo *et al*, 2001; Park *et al*, 2002). On the other hand, CFTR does not seem to regulate slc26a6 activity in the resting state because CFTR<sub>inh</sub>-172 and knock-down of CFTR did not reduce Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity of the unstimulated duct (Figure 4). Slc26a6 also regulates CFTR activity in the stimulated state by reducing the rate of CFTR activation at physiological stimulus intensity, which may also serve to prevent uncontrolled activation of CFTR.

The nature of the increased Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange and HCO<sub>3</sub><sup>-</sup> permeability in slc26a6<sup>-/-</sup> cells is not known with certainty. Partial inhibition of Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange by CFTR<sub>inh</sub>-172 indicates that part of the increased permeability is due to dis-regulation of CFTR. However, knock down of CFTR was more effective than CFTR<sub>inh</sub>-172 in reducing Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity, suggesting that an additional CFTR-dependent, but not CFTR-mediated, mechanism was active in the slc26a6<sup>-/-</sup> ducts. This conclusion is further supported by the finding that stimulation of the slc26a6<sup>-/-</sup> duct cells clearly activated CFTR Cl<sup>-</sup> current (Figure 6C) but did not appreciably increase the luminal HCO<sub>3</sub><sup>-</sup> permeability (Figure 5B). It is possible that activation of CFTR activates another luminal HCO<sub>3</sub><sup>-</sup> transporter like slc26a3. In our hand, activation of slc26a3 was not due to increased expression of slc26a3.

While this manuscript was under revision, another study examined the role of slc26a6 in pancreatic HCO<sub>3</sub><sup>-</sup> and fluid

secretion and reported several findings that are significantly different from the present study (Ishiguro *et al*, 2006). It is possible that this resulted from the difference in the animal models. There are several pieces of data that raise questions about the physiological relevance of the model used by Ishiguro *et al*. The most profound difference is the change in the expression of slc26a3 in the slc26a6<sup>-/-</sup> mice model used by Ishiguro *et al*, which examined slc26a3 expression by RT-PCR and reported a five-fold increase in slc26a3 mRNA. RT-PCR is susceptible to overestimation artefact and Ishiguro *et al* seemed to extract the mRNA from the entire pancreas. Using Q-PCR and extracting the mRNA from microdissected ducts, we did not detect any appreciable change in slc26a3 mRNA in two separate HCO<sub>3</sub><sup>-</sup>-secreting ducts, the pancreatic and SMG ducts. On the other hand, we evaluated the role of CFTR by CFTR<sub>inh</sub>-172 and downregulation with siRNA and showed that CFTR mediates a significant part of HCO<sub>3</sub><sup>-</sup> transport in the slc26a6<sup>-/-</sup> duct. Ishiguro *et al* did not examine the role of CFTR in their mice. In addition, Ishiguro *et al* saw no stimulation of Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange by forskolin in WT ducts, whereas we found strong stimulation (Figure 4). It is not clear how stimulation of CFTR did not increase Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity. Moreover, the Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in the WT ducts used by Ishiguro *et al* is very low, whereas the basal fluid secretion in these ducts is quite high. The pancreatic ducts of the WT mice obtained from our line show low spontaneous fluid secretion and significant CFTR-independent Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity (Figures 2 and 4). The increased spontaneous secretion in our ducts approaches the basal spontaneous secretion in the WT ducts used by Ishiguro *et al*. The high basal fluid secretion by the ducts used in the Ishiguro *et al* study may have masked the increased spontaneous secretion in slc26a6<sup>-/-</sup> ducts. It is not clear how mice strain can be so different, but these differences may explain the different results. We believe that probing the role of CFTR in the slc26a6<sup>-/-</sup> mice and the regulation of CFTR by slc26a6 *in vivo*, as was done in our study, is essential to reveal the interaction between transporters and its physiological significance.

Our results clearly show that slc26a6 is essential for stimulated fluid and HCO<sub>3</sub><sup>-</sup> secretion by the duct. Hence, slc26a6<sup>-/-</sup> ducts mediate mainly spontaneous secretion. A small, stimulated secretion could be elicited only by stimulation with a high concentration of forskolin. Importantly, even when the ducts were stimulated with 10 μM forskolin that rapidly and maximally activates CFTR Cl<sup>-</sup> current (Figure 6), stimulated fluid secretion by the slc26a6<sup>-/-</sup> ducts was not maximal. This indicates that slc26a6 plays an essential role and likely mediates a significant portion of fluid and HCO<sub>3</sub><sup>-</sup> secretion by the pancreatic duct.

The present work reveals the importance of SLC26A transporters and their interaction with CFTR in pancreatic duct fluid and HCO<sub>3</sub><sup>-</sup> secretion. It is likely that similar regulation takes place in other CFTR and SLC26A transporters expressing epithelia that secrete HCO<sub>3</sub><sup>-</sup>, such as the salivary glands, airways, the vas deferens and the intestine. Hence, these findings have important implications for CF and epithelial diseases owing to mutations in SLC26A transporters. On the one hand, replacing the Cl<sup>-</sup> channel function of CFTR is not likely to be sufficient to correct the pathologies of CF: restoration of the CFTR-regulated and SLC26A transporter-mediated HCO<sub>3</sub><sup>-</sup> secretion will also likely be required to



alleviate the symptoms of CF. On the other hand, although the activity and fluid and HCO<sub>3</sub><sup>-</sup> secretion by SLC26 transporters requires CFTR (Figures 2–5), if a way can be found to activate the SLC26 transporters, in particular SLC26A6, in the absence of CFTR, the lack of fluid and HCO<sub>3</sub><sup>-</sup> secretion in CF may be corrected, in part, to alleviate the symptoms of CF related to a lack of HCO<sub>3</sub><sup>-</sup> secretion.

## Materials and methods

The CFTR and slc26a6 clones and their cRNA were the same as those used in previous works (Ko *et al*, 2002; Shcheynikov *et al*, 2004). The HEPES-buffered bath solution for sealed pancreatic ducts and parotid cells (solution A) contained (in mM) 140 NaCl, 5 KCl, 1 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, 10 HEPES (pH 7.4 with NaOH) and 10 glucose. Cl<sup>-</sup>-free solutions were prepared by replacement of Cl<sup>-</sup> with gluconate. HCO<sub>3</sub><sup>-</sup>-buffered solutions were prepared by replacing 25 mM Na<sup>+</sup>-anion with 25 mM Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> and reducing HEPES to 2.5 mM. HCO<sub>3</sub><sup>-</sup>-buffered solutions were gassed with 5% CO<sub>2</sub> and 95% O<sub>2</sub>. The osmolarity of all solutions was adjusted to 310 mOsmol with the major salt. For experiments with *Xenopus* oocytes, the standard HEPES-buffered medium was ND96 composed of (in mM) 96 NaCl, 2 KCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 2.5 pyruvate and 5 HEPES-Na, pH 7.5 (Shcheynikov *et al*, 2004). The HCO<sub>3</sub><sup>-</sup>-buffered solution contained (in mM) 71 NaCl, 25 NaHCO<sub>3</sub>, 2 KCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub> and 5 HEPES-Na, pH 7.5.

### Generation of slc26a6<sup>-/-</sup> mice

The Slc26a6-targeting vector (Figure 1) was based on the plasmid pNot1-Pme-Srf (Herz *et al*, 1992), which contains a PolIII-neobPA cassette and two copies of the herpes simplex virus thymidine-kinase (*TK*) gene. A short arm (consisting of a 3-kb fragment spanning exons 1–6 of the slc26a6 gene) was amplified by using isogenic 120S6/SvEvTac murine genomic DNA and the following primer pairs: 5'-CCGGCTCGAGCCAGAATTCTGATTGCTGATC-3' and 5'-CCGGCTCGAGCTAGATAACGGACAGTGGCCAGA-3'. Sequences for the primer pairs were derived from Genbank (accession number NC 000075). An in-frame termination codon was placed at the 3'-end of the short arm and the fragment was cloned into the *XhoI* site of the vector. A 4-kb long arm fragment spanning from intron 9 to exon 18 was amplified with primers 5'-ATAA GAATGCGCGCCGAGCATCCCTAGCAAGTCTTCTTACACA and 5'-ATAAGAATGCGCGCCGCTCACACAGTTCACAAAAGGAGAGGGTGCT and was subcloned into the *NotI* site of the vector. Exons 6–9 were replaced by the *Neo* gene cassette. A linearized construct was introduced into murine SM-1 embryonic stem cells derived from the 129s6/SvEvTac strain by electroporation, and subsequent cloning of homologous recombinant colonies was carried out as described (Willnow and Herz, 1994). Two independent positive clones derived from the targeting construct were expanded and injected into C57BL/J blastocysts. High percentage chimeras derived from each clone were crossed with female C57BL/6J mice to generate two lines of animals carrying the disrupted slc26a6 allele. Phenotypic characterization was carried out in tissues derived from mixed C57BL/6J × 129SvEvTac animals. Slc26a6 in a congenic C57BL/6J animal was achieved by breeding for six generations before using for experiments.

### Immunolocalization

The immunolocalization procedure used has been described before (Ko *et al*, 2004). In brief, frozen pancreatic sections were immobilized by poly-L-lysine and permeabilized with 0.5 ml of cold methanol for 10 min at -20°C. The nonspecific sites were blocked with 5% goat serum, 1% BSA and 0.1% gelatin in PBS (blocking medium). The sections were incubated with a 1:100 dilution of anti-CFTR antibodies in blocking medium overnight at 4°C. Unbound antibodies were washed and the bound antibodies were detected with goat anti-rabbit IgG tagged with FITC. Images were captured with a Zeiss 510 Laser Scanning Confocal Microscope using a 63 × 1.3 NA PlanApo objective.

### Primary culture of pancreatic ducts

Age (6–10 months)- and sex-matched WT and slc26a6<sup>-/-</sup> mice were killed by cervical dislocation and the pancreas was removed and

injected with 5 ml digestion buffer composed of DMEM supplemented with soy beans trypsin inhibitor (STI) 0.2 mg/ml, BSA 2 mg/ml, hyaluronidase 400 U/ml (type IV-S, Sigma) and 50 U/ml collagenase (CLSPA, Worthington). The tissue was minced into 1–2 mm pieces, gassed with 5% CO<sub>2</sub> and 95% O<sub>2</sub>, and incubated at 37°C for 30 min and then in fresh digestion buffer for further 30 min. The digested tissue was washed with DMEM and resuspended in buffer composed of DMEM, 0.2 mg/ml STI and 30 mg/ml BSA. Intralobular ducts were microdissected from tissue fragments loosened by the digestion using sharp needles. The ducts were cultured in medium composed of DMEM supplemented with 0.1 mg/ml STI, 10% FBS and 2 mM glutamine. The ducts were cultured at 37°C in 5% CO<sub>2</sub> for 36 or up to 48 h. During overnight culture, the ends of the ducts were sealed, leading to a slow dilatation of the ducts lumen due to the accumulation of some fluid under resting conditions. These ducts are selected as healthy, active ducts and equilibrated in HEPES-buffered media to establish the resting state so that spontaneous secretion in response to incubation in HCO<sub>3</sub><sup>-</sup>-buffered media can be measured.

### Treatment with dicer siRNA

The ducts were transfected with CFTR-specific or scrambled negative control dicer substrate RNAi duplex (siRNA) within 3 h after dissection and incubated in culture media. The dicer siRNA sequences used were: siRNA1: GUUAAGAAUCCCACCGCUUU CAGCUU; siRNA2: GUGCAAAUUCAGAGCUUUGUGGAACAG and siRNA3: CAGAAGUGCCUGAAGGGAGUCGUACUG. The scrambled siRNA sequence was CUUCCUCUCUUCUCUCCUUGUGA. Isolated ducts were kept in 35 mm dishes containing 2 ml of DMEM with 10% FBS, but without antibiotics. In total, 100 pmol siRNA was diluted in 250 μl of Opti-MEM I Reduced Serum Medium and 5 μl of Lipofectamine 2000 was diluted in 250 μl of the same medium. After 5 min, the diluted siRNA and Lipofectamine 2000 were mixed and left at room temperature for 20 min before addition to the dish with the ducts. After 12 h, the medium was replaced with fresh medium without the siRNA and the ducts were used 36–48 h after the beginning of transfection.

### Fluid secretion by the sealed ducts

Fluid secretion was measured by video microscopy as described before (Szalmay *et al*, 2001). The sealed ducts were transferred to a perfusion chamber and perfused with HEPES- and then HCO<sub>3</sub><sup>-</sup>-buffered media containing the desired agonists. Images were captured at 2 or 5 min intervals and analyzed offline by calculating the lumen volume. Due to the variation in size between the microdissected ducts, a normalization procedure was used and the volume ( $V_0$ ) of the first image was set as 1. Secretion was expressed as the ratio  $V_t/V_0$ , which was calculated from area ratio ( $A_t/A_0$ ) of the duct assuming a cylinder (Szalmay *et al*, 2001) and using equation  $V_t/V_0 = (A_t/A_0)^{3/2}$ . Secretory rates were also calculated for the 10 min intervals of incubating the ducts in HEPES- and HCO<sub>3</sub><sup>-</sup>-buffered media and for the first 10 min of stimulation with secretin using the average diameter and length of each group (see Ishiguro *et al*, 1998; Szalmay *et al*, 2001).

### pH<sub>i</sub> measurements in the sealed ducts

The pH<sub>i</sub> of the sealed ducts was measured by microfluorometry as before (Ko *et al*, 2002). The sealed ducts were loaded with BCECF by incubating them for 20 min at room temperature with 2 μM of BCECF/AM. After stabilization of the fluorescence signal, the ducts were perfused with a bath solution without BCECF/AM for at least 10 min to allow completion of BCECF/AM hydrolysis and stabilization of pH<sub>i</sub> and ductal function. During the recovery, the ducts were perfused with a HEPES-buffered bath solution. BCECF fluorescence was measured at excitation wavelengths of 440 and 490 nm and collecting the light emitted at wavelengths above 530 nm. The ducts were perfused with HCO<sub>3</sub><sup>-</sup>-buffered solutions and after stabilization of pH<sub>i</sub>, Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity was measured by alternately incubating the ducts in Cl<sup>-</sup>-free and Cl<sup>-</sup>-containing medium. HCO<sub>3</sub><sup>-</sup> permeability of the luminal membrane was estimated by equilibrating the sealed ducts in HCO<sub>3</sub><sup>-</sup>-buffered media. Then, resting or stimulated ducts were exposed to media containing 1 μM HOE694 and 0.2 mM H<sub>2</sub>DIDS. The rate of the ensuing acidification was used as an index of luminal membrane HCO<sub>3</sub><sup>-</sup> permeability.

### Preparation of parotid duct cells

Parotid duct cells were prepared by the enzymatic digestion procedure described before (Ko *et al*, 2004). In brief, the glands were removed, cleaned and rapidly minced and treated with 0.025% trypsin for 7 min at 37°C. The digestion was stopped by a wash with a medium containing 1.5 mg/ml soybean trypsin inhibitor and the tissue was further digested for 20 min with 70 U/ml collagenase CLSPA. The liberated cells were washed, suspended in solution A containing 1.5 mg/ml soybean trypsin inhibitor and kept on ice until use.

### Current measurement in isolated parotid duct cells

The whole-cell configuration of the patch-clamp technique was used to measure the Cl<sup>-</sup> current as detailed before (Ko *et al*, 2004). The pipette solution contained (mM) 140 NMDG<sup>+</sup>-Cl<sup>-</sup>, 1 MgCl<sub>2</sub>, 2 EGTA, 5 ATP and 10 HEPES (pH 7.3 with Tris). The bath solution was Na<sup>+</sup>-free solution A. The current was recorded with an Axopatch 200A patch-clamp amplifier and digitized at 2 kHz. The membrane conductance was probed by stepping the membrane potential from a holding potential of 0 mV to membrane potentials between -80 and +60 mV at 10 mV steps for 200 ms with 500 ms intervals between steps. In some experiments, the current was recorded at a holding potential of -80 mV. Current recorded at -80 mV by both procedures was used to obtain the rate of current activation. Pipettes had resistance between 5 and 7 MΩ when filled with pipette solution and seal resistance was always more than 8 GΩ. Current recording and analysis was performed with pClamp

6.0.3 software and results were analyzed and figures were plotted with Origin 7.5 software.

### Current measurement in oocytes

Electrophysiological recordings were performed with a two-electrode voltage clamp using an OC-725C Oocyte Clamp System (Warner Instrument), as detailed before (Shcheynikov *et al*, 2004). The microelectrodes were filled with 3 M KCl and had a resistance of 0.5–2 MΩ. Current and voltage were digitized via a Digidata 1322A A/D converter (Axon Instrument, Foster City, CA) and analyzed using a Clampex 8.1 system.

### Statistical analysis

Results in all experiments are given as the mean ± s.e.m. of the indicated number of experiments. Significance analysis was performed by ANOVA.

## Acknowledgements

We thank Alan Verkman (University of California, San Francisco) for a gift of CFTR<sub>inh</sub>-172, and Jen-Chieh Chuang and Joyce Repa for help with the Q-PCR. This work was supported by NIH Grants DE12309, DK38938 (to SM), DK49835 (to PT) and training Grant GM-08203 (MRD), as well as CF Foundation Grant MUALLE05G0 (to SM).

## References

- Ahn W, Kim KW, Lee JA, Kim JY, Choi JY, Moe OM, Milgram SL, Muallem S, Lee MG (2001) Regulatory interaction between CFTR and HCO<sub>3</sub><sup>-</sup> salvage mechanisms in model systems and the mouse pancreatic duct. *J Biol Chem* **276**: 17236–17243
- Choi JY, Muallem D, Kiselyko K, Thomas PJ, Muallem S (2001) Aberrant CFTR-dependent HCO<sub>3</sub><sup>-</sup> transport in mutations associated with cystic fibrosis. *Nature* **410**: 94–97
- Clarke LL, Harline MC (1998) Dual role of CFTR in cAMP-stimulated HCO<sub>3</sub><sup>-</sup> secretion across murine duodenum. *Am J Physiol* **274**: G718–G726
- Cohn JA (2005) Reduced CFTR function and the pathobiology of idiopathic pancreatitis. *J Clin Gastroenterol* **39**: S70–S77
- Cook DI, Van Lennep EW, Roberts ML, Young JA (1994) Secretion by the major salivary glands. In *Textbook of Physiology of the Gastrointestinal Tract*, Johnson LR (ed), pp 1061–1117. New York: Raven Press
- Everett LA, Glaser B, Beck JC, Idol JR, Buchs A, Heyman M, Adawi F, Hazani E, Nassir E, Baxevasis AD, Sheffield VC, Green ED (1997) Pendred syndrome is caused by mutation in a putative sulphate transporter gene (PDS). *Nat Genet* **17**: 411–422
- Freel RW, Hatch M, Green M, Soleimani M (2006) Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. *Am J Physiol Gastrointest Liver Physiol* **290**: G719–G728
- Herz J, Clouthier DE, Hammer RE (1992) LDL receptor-related protein internalizes and degrades uPA–PAI-1 complexes and is essential for embryo implantation. *Cell* **71**: 411–422
- Irokawa T, Krouse ME, Joo NS, Wu JW, Wine JJ (2004) A 'virtual gland' method for quantifying epithelial fluid secretion. *Am J Physiol Lung Cell Mol Physiol* **287**: L784–L793
- Ishiguro H, Namkung W, Yamamoto A, Wang Z, Worrell RT, Xu J, Lee MG, Soleimani M (2006) Effect of Slc26a6 deletion on apical Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange activity and cAMP-stimulated bicarbonate secretion in pancreatic duct. *Am J Physiol Gastrointest Liver Physiol*. Aug 10; (Epub ahead of print)
- Ishiguro H, Naruse S, Steward MC, Kitagawa M, Ko SB, Hayakawa T, Case RM (1998) Fluid secretion in interlobular ducts isolated from guinea-pig pancreas. *J Physiol* **511**: 407–422
- Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS (2006) Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. *Nat Genet* **38**: 474–478
- Ko SB, Shcheynikov N, Choi JY, Luo X, Ishibashi K, Thomas PJ, Kim JY, Kim KH, Lee MG, Naruse S, Muallem S (2002) A molecular mechanism for aberrant CFTR-dependent HCO<sub>3</sub><sup>-</sup> transport in cystic fibrosis. *EMBO J* **21**: 5662–5672
- Ko SB, Zeng W, Dorwart MR, Luo X, Kim KH, Millen L, Goto H, Naruse S, Soyombo A, Thomas PJ, Muallem S (2004) Gating of CFTR by STAS domain of SLC26 transporters. *Nat Cell Biol* **6**: 343–350
- Kunzelmann K, Mall M (2002) Electrolyte transport in the mammalian colon: mechanisms and implications for disease. *Physiol Rev* **82**: 245–289
- Lee JH, Choi JH, Namkung W, Hanrahan JW, Chang J, Song SY, Park SW, Kim DS, Yoon JH, Suh Y, Jang IJ, Nam JH, Kim SJ, Cho MO, Lee JE, Kim KH, Lee MG (2003) A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. *Hum Mol Genet* **12**: 2321–2332
- Lee MG, Choi JY, Luo X, Strickland E, Thomas PJ, Muallem S (1999) Cystic fibrosis transmembrane conductance regulator regulates luminal Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange in mouse submandibular and pancreatic ducts. *J Biol Chem* **274**: 14670–14677
- Linsdell P, Tabcharani JA, Rommens JM, Hou YX, Chang XB, Tsui LC, Riordan JR, Hanrahan JW (1997) Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions. *J Gen Physiol* **110**: 355–364
- Liu XZ, Ouyang XM, Xia XJ, Zheng J, Pandya A, Li F, Du LL, Welch KO, Petit C, Smith RJ, Webb BT, Yan D, Arnos KS, Corey D, Dallos P, Nance WE, Chen ZY (2003) Prestin, a cochlear motor protein, is defective in non-syndromic hearing loss. *Hum Mol Genet* **12**: 1155–1162
- Lohi H, Kujala M, Kerkela E, Saarialho-Kere U, Kestila M, Kere J (2000) Mapping of five new putative anion transporter genes in human and characterization of SLC26A6, a candidate gene for pancreatic anion exchanger. *Genomics* **70**: 102–112
- Luo X, Choi JY, Ko SB, Pushkin A, Kurtz I, Ahn W, Lee MG, Muallem S (2001) HCO<sub>3</sub><sup>-</sup> salvage mechanisms in the submandibular gland acinar and duct cells. *J Biol Chem* **276**: 9808–9816
- Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galletta LJ, Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. *J Clin Invest* **110**: 1651–1658
- Makela S, Kere J, Holmberg C, Hoglund P (2002) SLC26A3 mutations in congenital chloride diarrhea. *Hum Mutat* **20**: 425–438
- Melvin JE, Yule D, Shuttleworth T, Begenisich T (2005) Regulation of fluid and electrolyte secretion in salivary gland acinar cells. *Annu Rev Physiol* **67**: 445–469
- Mount DB, Romero MF (2004) The SLC26 gene family of multifunctional anion exchangers. *Pflugers Arch Eur J Physiol* **447**: 710–721



- Park M, Ko SB, Choi JY, Muallem G, Thomas PJ, Pushkin A, Lee MS, Kim JY, Lee MG, Muallem S, Kurtz I (2002) The cystic fibrosis transmembrane conductance regulator interacts with and regulates the activity of the HCO<sub>3</sub><sup>-</sup> salvage transporter human Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransport isoform 3. *J Biol Chem* **277**: 50503–50509
- Poulsen JH, Fischer H, Illek B, Machen TE (1994) Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. *Proc Nat Acad Sci USA* **91**: 5340–5344
- Shcheynikov N, Kim KH, Kim KH, Dorwart MR, Ko SB, Goto H, Naruse S, Thomas PJ, Muallem S (2004) Dynamic control of cystic fibrosis transmembrane conductance regulator Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> selectivity by external Cl<sup>-</sup>. *J Biol Chem* **279**: 21857–21865
- Shcheynikov N, Wang Y, Park M, Ko SB, Dorwart M, Naruse S, Thomas PJ, Muallem S (2006) Coupling modes and stoichiometry of Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup> exchange by slc26a3 and slc26a6. *J Gen Physiol* **127**: 511–524
- Sohma Y, Gray MA, Imai Y, Argent BE (2000) HCO<sub>3</sub><sup>-</sup> transport in a mathematical model of the pancreatic ductal epithelium. *J Membr Biol* **176**: 77–100
- Sokol RZ (2001) Infertility in men with cystic fibrosis. *Curr Opin Pulm Med* **7**: 421–426
- Steward MC, Ishiguro H, Case RM (2005) Mechanisms of bicarbonate secretion in the pancreatic duct. *Annu Rev Physiol* **67**: 377–409
- Superti-Furga A, Hastbacka J, Wilcox WR, Cohn DH, van der Harten HJ, Rossi A, Blau N, Rimoin DL, Steinmann B, Lander ES, Gitzelmann R (1996) Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene. *Nat Genet* **12**: 100–102
- Szalmay G, Varga G, Kajiyama F, Yang XS, Lang TF, Case RM, Steward MC (2001) Bicarbonate and fluid secretion evoked by cholecystokinin, bombesin and acetylcholine in isolated guinea-pig pancreatic ducts. *J Physiol* **535**: 795–807
- Tuo B, Riederer B, Wang Z, Colledge WH, Soleimani M, Seidler U (2006) Involvement of the anion exchanger SLC26A6 in prostaglandin E<sub>2</sub><sup>-</sup> but not forskolin-stimulated duodenal HCO<sub>3</sub><sup>-</sup> secretion. *Gastroenterology* **130**: 349–358
- Wang Z, Wang T, Petrovic S, Tuo B, Riederer B, Barone S, Lorenz JN, Seidler U, Aronson PS, Soleimani M (2005) Renal and intestinal transport defects in Slc26a6-null mice. *Am J Physiol Cell Physiol* **288**: C957–C965
- Willnow TE, Herz J (1994) Homologous recombination for gene replacement in mouse cell lines. *Methods Cell Biol* **43**: 305–334
- Wilschanski M, Durie PR (1998) Pathology of pancreatic and intestinal disorders in cystic fibrosis. *J R Soc Med* **91**: 40–49
- Wright AM, Gong X, Verdon B, Linsdell P, Mehta A, Riordan JR, Argent BE, Gray MA (2004) Novel regulation of cystic fibrosis transmembrane conductance regulator (CFTR) channel gating by external chloride. *J Biol Chem* **279**: 41658–41663
- Xie Q, Welch R, Mercado A, Romero MF, Mount DB (2002) Molecular characterization of the murine SLC26a6 anion exchanger: functional comparison with SLC26a1. *Am J Physiol Renal Physiol* **283**: F826–F838